Comparative Pharmacology
Head-to-head clinical analysis: BUTAZOLIDIN versus XIBROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTAZOLIDIN versus XIBROM.
BUTAZOLIDIN vs XIBROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Also has uricosuric effect at higher doses.
XIBROM (bromfenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing intraocular inflammation.
Butazolidin (phenylbutazone) is typically administered orally at 100-200 mg 3 times daily with meals, not to exceed 600 mg/day. Initial loading dose of 400 mg may be given on day 1, followed by 300-400 mg/day in divided doses. Duration should be limited to 7-10 days.
Instill 1 drop into the affected eye(s) 4 times daily starting 24 hours before surgery and continuing for 2 weeks postoperatively.
None Documented
None Documented
Terminal half-life: 50-100 hours (prolonged in elderly or hepatic/renal impairment; accumulation risk evident within 5-7 days).
Terminal elimination half-life is approximately 42 hours. Clinical context: Due to its long half-life, steady-state is achieved after about 8 days of daily dosing, which contributes to sustained anti-inflammatory effect.
Primarily renal: ~60% as unchanged drug and glucuronide conjugates; biliary/fecal: ~40% (enterohepatic circulation).
Renal: ~70% (primarily as unchanged drug); Biliary/Fecal: ~15% (as metabolites); the remainder is eliminated via other minor pathways.
Category C
Category C
NSAID
NSAID